CorMedix Inc. — Director's Dealing 2013

Dec 16, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-12-13

Reporting Person: Lefkowitz Steven W (Director, Interim Chief Financial Ofcr)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-12-16	Common Stock, $0.001 par value per share	P	7500	$0.74	Acquired	141929	Direct
2013-12-13	Common Stock, $0.001 par value per share	P	10500	$0.8	Acquired	134429	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-13	Senior Convertible Note (convertible into Common Stock)	$0.35	C	42857	Disposed	2013-11-13	Common Stock, $0.001 par value per share (42857)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value per share	100000	Indirect
Common Stock, $0.01 par value per share	1000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (right to purchase Common Stock)	$3.4375	2015-03-24	Common Stock, $0.001 par value per share (5000)	5000	Direct
Stock Option (right to buy)	$0.9	2023-03-20	Common Stock, $0.001 par value per share (120000)	120000	Direct
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (150000)	150000	Direct
Warrant (right to purchase Common Stock)	$0.4	2017-11-13	Common Stock, $0.001 par value per share (37500)	37500	Direct
Warrant (right to purchase Common Stock)	$0.4	2017-09-20	Common Stock, $0.001 par value per share (87500)	87500	Indirect
Stock Option (right to buy)	$0.29	2022-01-06	Common Stock, $0.001 par value per share (30000)	30000	Direct
Stock Option (right to buy)	$1.1	2021-08-11	Common Stock, $0.001 par value per share (30000)	30000	Direct
Warrant	$3.4375	2015-03-24	Common Stock, $0.001 par value per share (19536)	19536	Direct

Footnotes

F1: The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).

F2: These options vest quarterly over two years beginning June 13, 2013.

F3: These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.

F4: The options vest in full on the first anniversary of the date of grant.

F5: The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

F6: (Right to buy Common Stock, $0.001 par value per share)

F7: The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.

F8: The reporting person's Form 4 filed September 23, 2013 mistakenly indicated the total number of securities beneficially owned was 181,072, when in fact the total number of securities beneficially owned is 100,000.